BTS
ADAP

BB&T Securities’s Adaptimmune Therapeutics ADAP Stock Holding History

BB&T Securities’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,867
Closed -$128K – 1583
2018
Q2 		$128K Buy
+10,867
New +$135K ﹤0.01% 1496

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

BB&T Securities's ADAP Position: Q3 2018 in Review

BB&T Securities sold out of Adaptimmune Therapeutics (ADAP) in Q3 2018, closing a stake of 10,867 shares — an estimated $128K sold.

BB&T Securities first reported a position in ADAP in Q2 2018 and held it in 1 quarter. The position peaked at $128K in Q2 2018. 93 funds tracked by Wall St. Rank hold ADAP as of Q3 2018.

  • BB&T Securities reported no remaining Adaptimmune Therapeutics position as of Q3 2018 after selling out during the quarter.
  • BB&T Securities sold 10,867 Adaptimmune Therapeutics shares in Q3 2018, an estimated $128K.
  • BB&T Securities first reported a position in Adaptimmune Therapeutics in Q2 2018 and held it in 1 quarter.
  • BB&T Securities's Adaptimmune Therapeutics position peaked at $128K in Q2 2018.
  • 93 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2018.

Based on BB&T Securities's 13F filing for Q3 2018, filed 14 Nov 2018.